Sir,
During a recent endoscopic dacryocystorhinostomy procedure on a patient taking selective serotonin reuptake inhibitors (SSRIs), we noticed engorgement of the nasal mucosa as well as severe early post-op epistaxis. We write to remind readers of the potential association between SSRIs and perioperative hemorrhage.
SSRIs (e.g. Citalopram, Fluoxetine, Fluvoxamine, and Sertraline) are commonly used to treat mood disorders such as depression, anxiety, and obsessive–compulsive disorders. Their popularity in the treatment of mood disorders stems from their side effect profile, which is better tolerated than the classic treatments (monoamine oxidase inhibitors, tricyclic antidepressants, etc).
One of the side effects of SSRIs of particular interest to us is the increased risk of bleeding perioperatively. It has already been documented that SSRIs increase the risk of gastrointestinal bleeding1 and intracranial hemorrhage.2 de Abajo3 summarizes the mechanism by which the SSRIs potentiate bleeding. Platelets cannot synthesize serotonin; rather, serotonin is stored in platelets and released by certain stimuli to induce vasoconstriction and platelet activation, and to enhance fibrin formation. This important neurotransmitter also helps in generating coated platelets, a subgroup of platelets with important procoagulant activity. As SSRIs inhibit the serotonin transporter, which is responsible for the uptake of serotonin into platelets, it could be predicted that SSRIs would deplete platelet serotonin, leading to a reduced ability to form clots and a subsequent increase in the risk of bleeding.
Although some clinical practice references suggest holding SSRIs for 2 or more weeks before surgery, it is difficult to frame a detailed strategy based on the available evidence.4, 5 Discontinuing SSRIs could lead to discontinuation syndrome, increased sensitivity to pain, and relapsing depression postoperatively. Furthermore, although the morbidity may be greater in patients under SSRIs, the mortality is still quite low.5 Consultation with a psychiatrist is recommended when there is high risk of morbidity from perioperative bleeding.
We write to remind readers to consider this potential association between the use of SSRIs and increased risk of hemorrhage, especially during the consent process for lacrimal surgery.
References
Yamamoto T, Abe K, Kuyama Y . Selective serotonin reuptake inhibitor and gastrointestinal hemorrhage. Nihon Rinsho 2013; 71 (4): 751–756.
Hackam DG, Mrkobrada M . Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79 (18): 1862–1865.
de Abajo FJ . Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011; 28 (5): 345–367.
Muluk V, Macpherson DS . Perioperative medication management. In Basow D, ed. UpToDate. UpToDate: Waltham, MA, 2013. http://www.uptodate.com/contents/perioperative-medication-management. (accessed 11 April 2014.
Auerbach AD, Vittinghoff E, Maselli J, Pekow PS, Young JQ, Lindenauer PK . Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med 2013; 173 (12): 1075–1081.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Saad, J., Ziahosseini, K., Wearne, G. et al. Selective serotonin reuptake inhibitors and perioperative bleeding in endoscopic dacryocystorhinostomy. Eye 28, 1268–1269 (2014). https://doi.org/10.1038/eye.2014.152
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2014.152